Method for obtaining biologically active recombinant human G-CSF
Provided is a method of obtaining biologically active recombinant human G-CSF from inclusion bodies, wherein the solubilization and refolding process can be performed at ambient temperature and the purification step comprises reversed phase chromatography (RP), in particular RP-HPLC. The G-CSF preparation so obtained is characterized by high purity and homogeneity.
1. A method for obtaining biologically active human G-CSF from inclusion bodies comprising the steps:
(a) solubilizing the G-CSF contained in the inclusion bodies with a solubilization buffer containing a denaturing agent and a reducing agent;
(b) refolding the G-CSF by diluting the solubilizate with a refolding buffer containing reduced and oxidized glutathione at a temperature >10° C.; and
(c) purifying the refolded G-CSF by a process comprising the steps:
(i) an ultra-/diafiltration step;
(ii) a CEX chromatography step;
(iii) a microfiltration step;
(iv) a RP chromatography step; and
(v) an ultra-/diafiltration step.
2. The method of claim 1 , wherein the denaturing agent is guanidine-HCI, preferably wherein the concentration of guanidine-HCI is 4.0 to 8.0 mol/l.
3. The method of claim 1 , wherein the reducing agent is DTT.
4. The method of claim 1 , wherein the concentration of the reducing agent in the solubilization buffer is 1 to 100 mmol/l.
5. The method of claim 1 , wherein 10 to 100 ml of solubilization buffer per gram of inclusion bodies are used.
6. The method of claim 1 , wherein the solubilization buffer and/or refolding buffer further contains a chelating agent.
7. The method of claim 1 , wherein the solubilization time is 1 to 10 hours.
8. The method of claim 1 , wherein the refolding buffer further contains arginine-HCl.
9. The method of claim 1 , wherein the concentration of reduced and oxidized glutathione is 0.2 to 10 mmol/l each.
10. The method of claim 1 , wherein the solubilizate is diluted with refolding buffer in a ratio of 1 to 20.
11. The method of claim 1 , wherein refolding is carried out at 20±2° C. for at least 3 hours.
12. The method of claim 1 , wherein the reversed phase (RP) chromatography step is RP high pressure liquid chromatography (RP-HPLC).
13. The method of claim 1 , wherein the RP chromatography step is preceded by an ion-exchange chromatography.
14. The method of claim 1 further comprising covalently attaching a water-soluble polymer to the G-CSF.
15. The method of claim 14 , wherein the molecular weight of the polymer is about 10 to 30 kDa.
16. A method for the production of a pharmaceutical composition of recombinant G-CSF and one or more pharmaceutically acceptable additive, wherein said method comprises the method for obtaining G-CSF of claim 1 .
17. The method of claim 16 , wherein the purified biologically active G-CSF is formulated in 10 mM acetic acid at a pH of 4.0, 0.0025% Polysorbate 80 and 50 g/l Sorbitol.